Better Access, Better Health: our Industry’s Vision on Sustainability of Healthcare Global Update of Generic Medicines in Developed Markets Making Generic and Biosimilar Manufacturing Thrive: A Global Policy A Concerted Approach to Tackle Economic and Regulatory Aspects of Shortages International Regulatory and Supply Chain Cooperation A New Value Proposition for Patients, Healthcare Practitioners and Systems Q&A with influential women in healthcare A Discussion with the Global Leaders Meet the Investors Global Policies of Biosimilar Medicines Unlocking Pharma Growth – Emerging Markets
Pricing and Reimbursement Policies around Generic and Biosimilar Medicines International Consensus Framework on Ethics in the Healthcare Sector AccessHealth, what’s behind a hashtag? Business Opportunities in External Markets and Access to Medicines – An Assessment of the Global Policy and Markets Committee
中華民國學名藥協會(Taiwan Generic Pharmaceutical Association, TGPA); 美國學名藥協會(Generic Pharmaceutical Association, GPhA); 加拿大學名藥協會(Canadian Generic Pharmaceutical Association, CGPA); 歐洲學名藥協會(原名European Generic and Biosimilar Medicines Association, EGA,現已更名為Medicines for Europe); 日本學名藥協會(Japan Generic Medicines Association, JGA); 南非學名藥協會(National Association of Pharmaceutical Manufacturers, NAPM); 約旦學名藥協會(Jordanian Association of Pharmaceutical Manufacturers, JAPM)。
澳洲學名藥協會(Generic and Biosimilar Medicines Association, GBMA); 墨西哥學名藥協會(Mexican Association of Generic Medicines, AMEGI); 巴西學名藥協會(Brazilian Generic Medicine Drugmakers Association, Progenericos); 馬來西亞藥品工業組織(Malaysian Organisation of Pharmaceutical Industries, MOPI)。